↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "(L773:1552 5279 OR L773:1552 5260) lar1:(lu) lar1:(ki) srt2:(2015)"

Search: (L773:1552 5279 OR L773:1552 5260) lar1:(lu) lar1:(ki) > (2015)

Result 1-3 of 3

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Bocchetta, Martina, et al. (author) The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. 2015 In: Alzheimer's & Dementia. - : Wiley. - 1552-5279 .- 1552-5260. ; 11:2, s. 195-206 Journal article (peer-reviewed)abstract We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.
2.	Kvartsberg, Hlin, 1987, et al. (author) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. 2015 In: Alzheimer's & dementia : the journal of the Alzheimer's Association. - : Wiley. - 1552-5279 .- 1552-5260. ; 11:10, s. 1180-1190 Journal article (peer-reviewed)abstract Synaptic dysfunction is an early event in Alzheimer's disease (AD) pathogenesis and directly related to cognitive impairment. Consequently, synaptic biomarkers may be valuable tools for both early diagnosis and disease stage. Neurogranin (Ng) is a postsynaptic protein involved in memory consolidation.
3.	Rosén, Christoffer, 1986, et al. (author) Benchmarking biomarker-based criteria for Alzheimer's disease : Data from the Swedish Dementia Registry, SveDem. 2015 In: Alzheimer's & Dementia. - : Elsevier. - 1552-5260 .- 1552-5279. ; 11:12, s. 1470-1479 Journal article (peer-reviewed)abstract INTRODUCTION: New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid-β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD-indicative cerebrospinal fluid (CSF) biomarker profile.METHODS: By cross-referencing a laboratory database with the Swedish Dementia Registry (SveDem), 2357 patients with data on CSF Aβ and tau biomarkers and a clinical diagnosis of AD with dementia were acquired.RESULTS: Altogether, 77.2% had pathologic Aβ42 and total tau or phosphorylated tau in CSF. These results were stable across age groups. Female sex and low mini-mental state examination score increased the likelihood of pathologic biomarkers.DISCUSSION: About a quarter of clinically diagnosed AD patients did not have an AD-indicative CSF biomarker profile. This discrepancy may partly reflect incorrect (false positive) clinical diagnosis or a lack in sensitivity of the biomarker assays.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-3 of 3

Refine your search

Type of publication: journal article (3)

Type of content: peer-reviewed (3)

Author/Editor: Blennow, Kaj, 1958 (2); Zetterberg, Henrik, ... (2); Eriksdotter, Maria (2); Minthon, Lennart (1); Wimo, Anders (1); Tsolaki, Magda (1); show more...; Pasquier, Florence (1); Olde Rikkert, Marcel (1); Lawlor, Brian (1); Brinkmalm, Gunnar (1); Ingelsson, Martin (1); Lannfelt, Lars (1); Portelius, Erik, 197 ... (1); Winblad, Bengt (1); Hansson, Oskar (1); Scheltens, Philip (1); van der Flier, Wiesj ... (1); Teunissen, Charlotte ... (1); Yener, Görsev (1); Martínez-Lage, Pablo (1); Lleó, Alberto (1); Kvartsberg, Hlin, 19 ... (1); Andreasson, Ulf, 196 ... (1); Nordberg, Agneta (1); Frisoni, Giovanni B. (1); Galluzzi, Samantha (1); Farahmand, Bahman (1); Andreasen, Niels (1); Andersson, Kerstin (1); Mattsson, Niklas, 19 ... (1); Skillbäck, Tobias (1); Visser, Pieter Jelle (1); Peters, Oliver (1); Jessen, Frank (1); Religa, Dorota (1); Nobili, Flavio (1); Jones, Roy W. (1); Nägga, Katarina (1); Kilander, Lena (1); Öhrfelt, Annika, 197 ... (1); Wallin, Åsa (1); Bocchetta, Martina (1); Kehoe, Patrick Gavin (1); Aguera, Eduardo (1); Bernabei, Roberto (1); Bullock, Roger (1); Ceccaldi, Mathieu (1); Dartigues, Jean-Fran ... (1); de Mendonça, Alexand ... (1); Didic, Mira (1); show less...

University: Lund University (3); Karolinska Institutet (3); University of Gothenburg (2); Uppsala University (2); Linköping University (1)

Language: English (3)

Research subject (UKÄ/SCB): Medical and Health Sciences (3)

Year: 2015 (3)Undo refine

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view